Atlas Energy Corp. Announces Appointments to Subsidiary Board and Extension of TSXV Sandbox Exit Deadline
Atlas Energy Reports First Quarter 2026 Financial Results
Atlas Energy Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Operations and Filing of Its 2025 AIF
WILLOW BIOSCIENCES REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS
WILLOW BIOSCIENCES INC. ANNOUNCES COMPLETION OF SALE OF OPERATING SUBSIDIARY AND MANAGEMENT CHANGES
WILLOW BIOSCIENCES ANNOUNCES ANNUAL GENERAL AND SPECIAL MEETING VOTING RESULTS
WILLOW BIOSCIENCES REPORTS 2024 FINANCIAL RESULTS AND UPDATE REGARDING SALE OF OPERATING SUBSIDIARY
WILLOW ANNOUNCES INITIATION OF STRATEGIC REVIEW PROCESS
WILLOW BIOSCIENCES REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
WILLOW BIOSCIENCES ANNOUNCES NEW PARTNERSHIP WITH A GLOBAL INGREDIENT MANUFACTURER TO ADVANCE DEVELOPMENT OF A HIGH VALUE INGREDIENT FROM ITS PORTFOLIO
Willow Biosciences announces second collaboration with leading API manufacturer
WILLOW ANNOUNCES A SECOND PROGRAM WITH GLOBAL INGREDIENT MANUFACTURER TO DEVELOP AN ENZYME FOR MANUFACTURING A LARGE VOLUME ACTIVE PHARMACEUTICAL INGREDIENT
Willow Biosciences inks commercial partnership with Kalsec
WILLOW ANNOUNCES COMMERCIAL LICENSE AND ROYALTY AGREEMENT WITH KALSEC INC.
Willow Biosciences CEO confident in future after record revenue and new partnerships - ICYMI
Willow Biosciences achieves record revenue for the second quarter
WILLOW BIOSCIENCES REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
Willow Biosciences lands biopesticides collaboration worth $2M in year one
Willow Biosciences lands biopesticides collaboration worth $2mln in year one
WILLOW BIOSCIENCES ANNOUNCES NEW FUNDED BIOPESTICIDES RESEARCH AND DEVELOPMENT PARTNERSHIP AFTER SUCCESSFULLY COMPLETING FEASIBILITY STUDY
Willow Biosciences secures $1.6M for research and product development
Willow Biosciences projecting over $1M in 2Q revenue
WILLOW BIOSCIENCES PROVIDES CORPORATE UPDATE AND ANNOUNCES SIGNING OF A NEW PARTNERED PROGRAM
Willow Biosciences to launch a $3m brokered placement
Willow Biosciences inks API manufacturing deal with Laurus Labs
WILLOW ANNOUNCES MULTI-PRODUCT DEVELOPMENT AND LICENSING PARTNERSHIP WITH LAURUS LABS FOR MANUFACTURING ACTIVE PHARMACEUTICAL INGREDIENTS
Willow Biosciences anticipating large strategic partnership
WILLOW BIOSCIENCES REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
Willow Biosciences expects first commercial revenues in 2024
WILLOW BIOSCIENCES REPORTS FOURTH QUARTER AND FISCAL YEAR 2023 FINANCIALS AND OPERATIONS AND FILING OF ITS 2023 AIF
Willow Biosciences unveils second strategic investment from Kalsec
WILLOW BIOSCIENCES ANNOUNCES SECOND STRATEGIC INVESTMENT FROM KALSEC
Willow Biosciences unveils cash injection for natural ingredients development
WILLOW BIOSCIENCES ANNOUNCES STRATEGIC INVESTMENT FROM KALSEC TO DEVELOP INNOVATIVE NATURAL FOOD INGREDIENTS
Willow Biosciences announces partnership with leading API manufacturer
WILLOW ANNOUNCES COLLABORATION WITH GLOBAL INGREDIENT MANUFACTURER TO DEVELOP A MORE COST-EFFECTIVE, SUSTAINABLE PROCESS FOR A LARGE VOLUME ACTIVE PHARMACEUTICAL INGREDIENT
Willow Biosciences announces collaboration to develop sustainable intermediates and active pharma ingredients
WILLOW ANNOUNCES COLLABORATION WITH ENTERIN TO DEVELOP SUSTAINABLE INTERMEDIATES AND ACTIVE PHARMACEUTICAL INGREDIENTS
Willow Biosciences primes investors for strong 2024 after transformative 2023
WILLOW PLANS FOR SIGNIFICANT GROWTH IN 2024 ON THE BACK OF A SUCCESSFUL 2023
Willow Biosciences set to generate revenue from partnership with biopharma firm as early as 2024
Willow Biosciences advances development program with leading innovative biopharma company
WILLOW AND LEADING INNOVATIVE BIOPHARMACEUTICAL COMPANY ADVANCE DEVELOPMENT PROGRAM TO MANUFACTURE SUSTAINABLE INTERMEDIATES AND ACTIVE PHARMACEUTICAL INGREDIENTS
Willow Biosciences reduces cash burn, achieves record revenue in 3Q
WILLOW BIOSCIENCES ANNOUNCES COMPLETION OF PREVIOUSLY ANNOUNCED CONVERTIBLE DEBENTURE FINANCING
Willow Biosciences and Suanfarma partner to develop large volume anti-infective API through precision fermentation
WILLOW AND SUANFARMA ANNOUNCE COLLABORATION ON DEVELOPMENT OF LARGE VOLUME ANTI-INFECTIVE API THROUGH PRECISION FERMENTATION
Willow Biosciences announces $1.2M debt offering
Willow Biosciences completes R&D to produce ursodeoxycholic acid